scholarly journals Glycogen Rich Clear Cell Carcinoma Pada Payudara

2019 ◽  
Vol 6 (2) ◽  
pp. 146-149
Author(s):  
Finot Finot ◽  
Dik Puspasari ◽  
Siti Amarwati
Keyword(s):  
Breast Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Periodic Acid ◽  
Low Grade ◽  
Breast Cancers ◽  
Signet Ring ◽  
Pas Staining

Background: Glycogen rich clear cell carcinoma is a rare neoplasm of the breast, with the incidence of 1.4-3% of all breast cancers. The tumour has distinct morphology, different from that of common breast cancers. Glycogen rich clear cell carcinomas are members of a heterogeneous group of neoplasms, including signet-ring, secretory and lipid-rich carcinomas of the breast. In general, clear cell breast carcinoma tends to follow an aggressive clinical course. Case report: To present a case of a 47 years old woman suffering from breast mass in the upper outer quadrant of her right breast. On macroscopic examination, the biopsy tumor sized 2x1.5x0.5 cm and solid with brown and white. Discussion: Microscopic examination showed breast tissue composed of tumor cells arranged in nets, trabeculae and singly dispersed. Tumor cells are moderately pleomorphic, have sharply defined border and polygonal contours. Cytoplasm is clear in more than 90% of cells and finely granular in few cells. Nuclei are hyperchromatic with clumped chromatin and prominent nucleoli. Occasional mitosis is also observed. Special stain (PAS Staining): Intracytoplasmic PAS positivity in tumor cells are variable. Immunohistochemistry ER (+) positive >20-50%, PR (+) positive <20%, HER2 (-) negative. The patient was diagnosed with glycogen rich clear cell carcinoma. Conclusion: Glycogen rich clear cell carcinoma of the breast is rare. Its clinical feature is rather aggressive and varies depending on special characteristics such as low grade. Keywords: Glycogen rich clear cell carcinoma, breast carcinoma, PAS staining   Latar belakang: Glycogen rich clear cell carcinoma adalah kanker payudara yang jarang, dengan insidensi 1.4-3% dari semua kanker payudara. Tumor memiliki morfologi yang berbeda dari kanker payudara pada umunya. Glycogen rich clear cell carcinoma merupakan neoplasma heterogen yang termasuk karsinoma payudara signet-ring, sekretori dan kaya lipid. Secara umum, carcinoma ini cenderung mengikuti perjalanan klinis yang agresif. Tujuan: Laporan Kasus: Dilakukan pemeriksaan makroskopis jaringan tumor dari seorang perempuan berusia 47 tahun dengan massa payudara kanan di kuadran luar atas. Tumor biopsi berukuran 2x1.5x0.5 cm, komposisi padat, berwarna coklat dan putih. Dilakukan pemeriksaan histopatologi, imunohistokimia dan histokimia pewarnaan khusus PAS (Periodic Acid Schiff). Pembahasan: Pemeriksaan mikroskopis menunjukkan jaringan payudara dengan sel-sel tumor yang tersusun dalam jaring, trabekula dan tersebar tunggal. Sel-sel tumor cukup pleomorfik, hiperkromatik, kromatin kasar dan nucleoli prominent, mitosis dapat ditemukan, sitoplasma jernih lebih dari 90% sel dan granular halus dalam beberapa sel, memiliki garis batas dan beberapa bentuk poligon yang jelas. Hasil histokimia PAS (+) positif, Immunohistokimia ER (+) positif > 20-50% pada sel-sel tumor, PR (+) positif < 20%, HER2 (-) negatif. Dari hasil pemeriksaan tersebut, pasien didiagnosis Glycogen rich clear cell carcinoma. Kesimpulan: Glycogen rich clear cell carcinoma pada payudara adalah tumor yang jarang, perilaku klinisnya dilaporkan agak agresif sejauh ini, sangat bervariasi tergantung pada karakteristik khusus seperti tingkat rendah. Kata kunci: Glycogen rich clear cell carcinoma, karsinoma payudara, pewarnaan PAS.

HER-2/neu expression in ovarian clear cell carcinomas

2003 ◽  
Vol 13 (1) ◽  
pp. 28-31 ◽  
Author(s):  
H. Iwamoto ◽  
H. Fukasawa ◽  
T. Honda ◽  
S. Hirata ◽  
K. Hoshi
Keyword(s):  
Breast Carcinoma ◽  
Cell Carcinoma ◽  
San Francisco ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Metastatic Breast ◽  
Breast Carcinomas ◽  
Ovarian Clear Cell Carcinoma ◽  
Clinical Prognosis ◽  
Her 2

HER-2 /neu is a 185-kDa glycoprotein and a transmembrane receptor with tyrosine kinase activity. Its overexpression is observed in 25–30% of primary breast carcinomas and is associated with a poor clinical prognosis. Recently, the U.S. Food and Drug Administration and the Japanese Ministry of Health, Welfare, and Labor approved the use of trastuzumab (Herceptin, Genentech, South San Francisco, CA) for the treatment of patients with metastatic breast carcinomas overexpressing HER-2 /neu. Results of clinical trials with Herceptin suggest that it may prolong the survival of patients with advanced metastatic breast carcinoma. Relatively little is known concerning the relationship between HER-2 /neu status and ovarian clear cell carcinoma. If HER-2 /neu overexpression status were demonstrable in ovarian clear cell carcinoma and a clinical correlation between overexpression and prognosis could be established, a rationale for clinical use of Herceptin for this tumor could be established. Our aim was to evaluate HER-2 /neu status in ovarian clear cell carcinomas. Fifteen ovarian clear cell carcinoma cases were immunostained for HER-2 /neu using HercepTest (DAKO, Glostrup, Denmark). Overexpression of HER-2 /neu was detected in only one case. Unlike in breast carcinoma, HER-2 /neu overexpression appeared to be uncommon in ovarian clear cell carcinomas. Herceptin may thus target only a small proportion of ovarian clear cell carcinomas and be of limited clinical value for treatment of this carcinoma.

Patterns of Care and Outcome of Clear Cell Carcinoma of the Head and Neck

2019 ◽  
Vol 161 (1) ◽  
pp. 98-104 ◽  
Author(s):  
Jamie Oliver ◽  
Peter Wu ◽  
Clifford Chang ◽  
Dylan Roden ◽  
Binhuan Wang ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Salivary Glands ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Tumor Grade ◽  
Low Grade ◽  
Major Salivary Gland ◽  
Positive Margins

Objective Clear cell carcinoma (CCC) is a rare salivary gland malignancy, believed to be generally low grade. We investigated CCC epidemiology and clinical behavior, using the National Cancer Database (NCDB). Study Design Retrospective cohort study. Setting NCDB. Subjects and Methods All CCCs of the salivary glands were selected between 2004 and 2015. Patient demographics, tumor characteristics, treatments, and survival were analyzed. Cox regression analyses were performed in treated patients. Results We identified 268 patients with CCC. Median age was 61 (21-90) years. Most were female (145, 54%). The most common site was oral cavity (119, 44%), followed by major salivary glands (68, 25%) and oropharynx (41, 15%). Most tumors were low grade (81, 68%) and stages I to II (117, 60.6%). Nodal (36, 17.5%) and distant metastases (6, 2.4%) were rare. Most were treated by surgery alone (134, 50.0%), followed by surgery and radiotherapy (69, 25.7%). Five-year overall survival (OS) was 77.6% (95% CI, 71.4%-84.2%). In univariate analysis, older age, major salivary gland and sinonasal site, stages III to IV, high grade, and positive margins were associated with worse OS. In multivariate analysis, only high tumor grade (hazard ratio [HR], 5.76; 95% CI, 1.39-23.85; P = .02), positive margins (HR, 4.01; 95% CI, 1.20-13.43; P = .02), and age ≥60 years (HR, 3.45; 95% CI, 1.39-8.55; P = .01) were significantly associated with OS. Conclusion We report the largest series of clear cell carcinomas of the head and neck. Outcomes are generally favorable following surgical-based treatments. In this series, pathologic tumor grade is associated with worse survival. Routine evaluation and reporting of tumor grade might better guide physicians in recommending appropriate treatments in this rare malignancy.

scholarly journals A Case of Hyalinizing Clear Cell Carcinoma, So-Called Clear Cell Carcinoma, Not Otherwise Specified, of the Minor Salivary Glands of the Buccal Mucosa

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Takahiro Yamanishi ◽  
Kiwako Kutsuma ◽  
Keisuke Masuyama
Keyword(s):  
Cell Carcinoma ◽  
Salivary Glands ◽  
Tumor Cells ◽  
Buccal Mucosa ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Minor Salivary Glands ◽  
Hyalinizing Clear Cell Carcinoma ◽  
Not Otherwise Specified ◽  
The Right

Hyalinizing clear cell carcinoma (HCCC), so-called clear cell carcinoma, not otherwise specified (CCC (NOS)), of the salivary glands is a rare and low-grade malignant tumor. We report a case of HCCC so-called CCC (NOS) (referred to as HCCC) of the minor salivary gland of the buccal mucosa. A 52-year-old woman had presented with a gradually growing and indolent mass in the right buccal mucosa for about two years. The first biopsy histopathologically suggested the possibility of malignancy derived from the minor salivary glands. A month later, she visited our hospital. The tumor measured approximately 1.5 cm in diameter and was elastic hard, smooth, and well movable. Image examinations demonstrated internal homogeneity of the lesion, which had a smooth margin, in the right buccal mucosa. Complete tumor resection followed by covering with a polyglycolic acid sheet and fibrin glue spray was performed without surgical flap reconstruction. Histopathological findings revealed proliferating tumor cells with clear cytoplasm surrounded by hyalinizing stroma in the submucosal minor salivary glands. Immunohistochemical stains revealed these tumor cells to be positive for epithelial cell markers but negative for myoepithelial ones. These findings confirmed the diagnosis of HCCC. Good wound healing and no evidence of local recurrence and metastasis have been shown since surgery.

scholarly journals Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Eriko Nakamura ◽  
Yuichiro Sato ◽  
Sayaka Moriguchi ◽  
Atsushi Yamashita ◽  
Takashi Higo ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Tumor Cells ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
English Literature ◽  
Borderline Tumor ◽  
Borderline Tumors ◽  
First Case ◽  
Napsin A ◽  
Unusual Combination

Ovarian seromucinous borderline tumors (SMBTs) are rare. They architecturally resemble serous borderline tumors but are much more frequently associated with endometriosis. The coexistence of other tumors with seromucinous tumors is also extremely rare. Here, we report an unusual combination of bilateral ovarian SMBT and clear cell carcinoma associated with polypoid endometriosis of the colon, in a 62-year-old woman. There was no transitional lesion between the two tumors. Immunohistochemistry showed different staining patterns in tumor components. Seromucinous tumor cells were positive for estrogen receptor (ER) and progesterone receptor (PgR) but negative for Napsin A, p504S, and HNF1B. Clear cell tumor cells were positive for Napsin A and p504S and focally positive for HNF1B but negative for ER and PgR. Loss of ARID1A expression was not observed in SMBTs, clear cell tumors, or endometriosis. These findings suggest that these tumors arose from separate endometriosis foci and collided within the same ovary. To the best of our knowledge, this is the first case of this unusual combination of ovarian seromucinous tumor and clear cell carcinoma to be reported in the English literature.

scholarly journals Glycogen-rich clear cell carcinoma of the feline mammary gland: case report

2016 ◽  
Vol 68 (5) ◽  
pp. 1117-1120
Author(s):  
C.B. Campos ◽  
C.O. Gamba ◽  
K.A. Damasceno ◽  
G.E. Lavalle ◽  
G.D. Cassali
Keyword(s):  
Mammary Gland ◽  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Regional Metastases ◽  
Microscopic Evaluation ◽  
Clear Cytoplasm ◽  
Pas Staining ◽  
Unilateral Mastectomy

ABSTRACT The aim of this report is to describe the first histopathological, immunohistochemical, and clinical characteristics of a feline glycogen-rich clear cell carcinoma (GRCCC). A Persian queen was admitted with mammary gland tumors and underwent radical unilateral mastectomy. Overall survival was considered 33 days and death was due to clinical evolution of the disease. Microscopic evaluation demonstrated epithelial cells arranged in a predominantly solid pattern, tumor cells presented an ample, granular, and foamy clear cytoplasm, and moderate cellular pleomorfism. The presence of cytoplasmatic glycogen was confirmed through diastase digestion followed by PAS staining. Histopathological and histochemical findings lead to the diagnosis of GRCCC with regional metastases.

scholarly journals Clear Cell Carcinoma of the Thymus: An Improbable Enemy

2021 ◽  
Author(s):  
Fábio Rêgo Salgueiro ◽  
Paulo Cunha ◽  
Diana Miranda ◽  
Tatiana Pereira ◽  
Filipa Pontes ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Anterior Mediastinum ◽  
Signet Ring Cell ◽  
Bilateral Hilar Lymphadenopathy ◽  
Signet Ring ◽  
Pulmonary Parenchyma ◽  
Ring Cell ◽  
High Level

Introduction: Thymic clear cell carcinoma is the most uncommon subtype of thymic carcinoma, with 20 cases reported worldwide. Case Description: We present the case of a 61-year-old female with dyspnoea and chest pain for 2 days. Computed tomography (CT) angiography showed pulmonary thromboembolism and the existence of mediastinal and bilateral hilar lymphadenopathy, the largest infracarinal with an inferior axis of 25 mm, and also, micronodules on the left pulmonary parenchyma. The patient was admitted for aetiological assessment and underwent anticoagulant therapy. After a month, she had an ischaemic stroke, the sequelae of which proved to be fatal. The autopsy showed a mass in the superior-anterior mediastinum, with dimensions of 11×8×6 cm, corresponding to a thymus signet ring cell primary carcinoma. The immunohistochemistry study revealed that this mass was positive for AE1/AE3, CK5/6 and CK7. Conclusion: The clinical, morphological and immunophenotypic diversity of this tumour makes its diagnosis a difficult multidisciplinary challenge, which requires a high level of clinical knowledge and accurate imaging and histological investigation.

Salivary Clear Cell Carcinoma Clinicopathologic Characteristics and Outcomes: A Population-Based Analysis

2019 ◽  
Vol 128 (11) ◽  
pp. 989-996 ◽  
Author(s):  
Daniel D. Sharbel ◽  
Aykut A. Unsal ◽  
Michael W. Groves ◽  
William G. Albergotti ◽  
J. Kenneth Byrd
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Hazard Ratio ◽  
Low Grade ◽  
Level Of Evidence ◽  
Clinicopathologic Characteristics ◽  
Clinicopathologic Factors ◽  
Localized Disease ◽  
Worse Prognosis

Background: Salivary clear cell carcinoma is an uncommon, low-grade malignancy for which limited data describing predictive clinicopathologic factors and treatment outcomes exist because of rarity. Methods: The authors queried the Surveillance, Epidemiology, and End Results database from 1982 to 2014. Multivariate Cox and Kaplan-Meier analyses were performed to determine disease-specific survival (DSS) and predictive clinicopathologic factors. Results: One hundred ninety-eight patients with salivary clear cell carcinoma were included. Overall incidence was 0.011 per 100 000 individuals, with no significant annual percentage change across years (−0.93%, P = .632). Five-, 10-, and 20-year DSS rates were 81.3% (n = 117), 69.6% (n = 94), and 55.3% (n = 68), respectively. Men (hazard ratio, 4.74; P = .0087) and patients with regional (hazard ratio, 5.59; P = .018) or distant (hazard ratio, 8.9; P = .01) metastases carried a worse prognosis. Five-year DSS was greater in patients with localized disease (96.36%, P < .0001) than those with regional or distant metastases. Treatment with surgery alone had better 10-year DSS (86.3%) compared with treatment with combination radiation and surgery (57.6%) or radiation monotherapy (18.75%, P < .0001). Conclusions: Salivary clear cell carcinoma carries an overall good prognosis. Patients with localized disease and those treated with surgery alone have more favorable prognoses. Male patients and those with regional or distant metastatic disease at time of presentation carry a worse prognosis. Level of Evidence: N/A

Sign in / Sign up

Export Citation Format

Share Document